Anti-CD3 antibodies: Towards clinical antigen-specific immunomodulation

Current Opinion in Pharmacology

Volumn 4, Issue 4, 2004, Pages 403-407

  Chatenoud, Lucienne ^a  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CD28 ANTIGEN; CD3 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; CORTICOSTEROID DERIVATIVE; CYCLOSPORIN A; FC RECEPTOR; IMMUNOMODULATING AGENT; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 4; INTERLEUKIN 5; MONOCLONAL ANTIBODY; OKT 3; PADGEM PROTEIN; T LYMPHOCYTE RECEPTOR; TRANSFORMING GROWTH FACTOR BETA;

ACUTE GRAFT REJECTION; ANTIGEN SPECIFICITY; ARTICLE; AUTOIMMUNE DISEASE; CLINICAL TRIAL; DRUG INDICATION; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TARGETING; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY GRAFT REJECTION; MITOGENICITY; NONHUMAN; PRIORITY JOURNAL; PSORIATIC ARTHRITIS;

EID: 3342935958     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coph.2004.03.012     Document Type: Review

References (40)

1. Kohler G. Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity Nature 256 1975 495-497
2. Kung P. Goldstein G. Reinherz E.L. Schlossman S.F. Monoclonal antibodies defining distinctive human T cell surface antigens Science 206 1979 347-349
3. Cosimi A.B. Colvin R.B. Burton R.C. Rubin R.H. Goldstein G. Kung P.C. Hansen W.P. Delmonico F.L. Russell P.S. Use of monoclonal antibodies to T-cell subsets for immunologic monitoring and treatment in recipients of renal allografts N Engl J Med 305 1981 308-314
4. Ortho Multicenter Transplant Study Group: A randomized clinical trial of OKT3 monoclonal antibody for acute rejection of cadaveric renal transplants. N Engl J Med 1985, 313 337-342.
5. Vigeral P. Chkoff N. Chatenoud L. Campos H. Lacombe M. Droz D. Goldstein G. Bach J.F. Kreis H. Prophylactic use of OKT3 monoclonal antibody in cadaver kidney recipients. Utilization of OKT3 as the sole immunosuppressive agent Transplantation 41 1986 730-733
6. Davis MM, Chien YH: T cell antigen receptors. In Fundamental Immunology. Edited by Paul W. New York: Raven Press; 1999 341-366.
7. Van Wauwe J.P. De Mey J.R. Goossens J.G. OKT3: a monoclonal anti-human T lymphocyte antibody with potent mitogenic properties J Immunol 124 1980 2708-2713
8. Chatenoud L. Legendre C. Ferran C. Bach J.F. Kreis H. Corticosteroid inhibition of the OKT3-induced cytokine-related syndrome-dosage and kinetics prerequisites Transplantation 51 1991 334-338
9. Abramowicz D. Schandene L. Goldman M. Crusiaux A. Vereerstraeten P. De Pauw L. Wybran J. Kinnaert P. Dupont E. Toussaint C. Release of tumor necrosis factor, interleukin-2, and gamma-interferon in serum after injection of OKT3 monoclonal antibody in kidney transplant recipients Transplantation 47 1989 606-608
10. Hirsch R. Gress R.E. Pluznik D.H. Eckhaus M. Bluestone J.A. Effects of in vivo administration of anti-CD3 monoclonal antibody on T cell function in mice. II. In vivo activation of T cells J Immunol 142 1989 737-743
11. Ferran C. Sheehan K. Dy M. Schreiber R. Merite S. Landais P. Noel L.H. Grau G. Bluestone J. Bach J.F. et al. Cytokine-related syndrome following injection of anti-CD3 monoclonal antibody: further evidence for transient in vivo T cell activation Eur J Immunol 20 1990 509-515
12. Alegre M. Vandenabeele P. Flamand V. Moser M. Leo O. Abramowicz D. Urbain J. Fiers W. Goldman M. Hypothermia and hypoglycemia induced by anti-CD3 monoclonal antibody in mice: role of tumor necrosis factor Eur J Immunol 20 1990 707-710
13. Van Lier R.A. Boot J.H. De Groot E.R. Aarden L.A. Induction of T cell proliferation with anti-CD3 switch-variant monoclonal antibodies: effects of heavy chain isotype in monocyte-dependent systems Eur J Immunol 17 1987 1599-1604
14. Hirsch R. Bluestone J.A. De Nenno L. Gress R.E. Anti-CD3 F(ab′)2 fragments are immunosuppressive in vivo without evoking either the strong humoral response or morbidity associated with whole mAb Transplantation 49 1990 1117-1123
15. Parlevliet K.J. Ten Berge I.J. Yong S.L. Surachno J. Wilmink J.M. Schellekens P.T. In vivo effects of IgA and IgG2a anti-CD3 isotype switch variants J Clin Invest 93 1994 2519-2525
16. Chatenoud L. Primo J. Bach J.F. CD3 antibody-induced dominant self tolerance in overtly diabetic NOD mice J Immunol 158 1997 2947-2954
17. Chatenoud L. Thervet E. Primo J. Bach J.F. Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice Proc Natl Acad Sci USA 91 1994 123-127
18. Hughes C. Wolos J.A. Giannini E.H. Hirsch R. Induction of T helper cell hyporesponsiveness in an experimental model of autoimmunity by using nonmitogenic anti-CD3 monoclonal antibody J Immunol 153 1994 3319-3325
19. Herold K.C. Bluestone J.A. Montag A.G. Parihar A. Wiegner A. Gress R.E. Hirsch R. Prevention of autoimmune diabetes with nonactivating anti-CD3 monoclonal antibody Diabetes 41 1992 385-391
20. Johnson B.D. Mccabe C. Hanke C.A. Truitt R.L. Use of anti-CD3 epsilon F(ab′)2 fragments in vivo to modulate graft-versus-host disease without loss of graft-versus-leukemia reactivity after MHC-matched bone marrow transplantation J Immunol 154 1995 5542-5554
21. Bolt S. Routledge E. Lloyd I. Chatenoud L. Pope H. Gorman S.D. Clark M. Waldmann H. The generation of a humanized, non-mitogenic CD3 monoclonal antibody which retains in vitro immunosuppressive properties Eur J Immunol 23 1993 403-411
22. Alegre M.L. Peterson L.J. Xu D. Sattar H.A. Jeyarajah D.R. Kowalkowski K. Thistlethwaite J.R. Zivin R.A. Jolliffe L. Bluestone J.A. A non-activating 'humanized' anti-CD3 monoclonal antibody retains immunosuppressive properties in vivo Transplantation 57 1994 1537-1543
23. Smith J.A. Tang Q. Bluestone J.A. Partial TCR signals delivered by FcR-nonbinding anti-CD3 monoclonal antibodies differentially regulate individual Th subsets J Immunol 160 1998 4841-4849
24. Smith J.A. Tso J.Y. Clark M.R. Cole M.S. Bluestone J.A. Nonmitogenic anti-CD3 monoclonal antibodies deliver a partial T cell receptor signal and induce clonal anergy J Exp Med 185 1997 1413-1422
25. Chatenoud L. CD3-specific antibody-induced active tolerance: from bench to bedside Nat Rev Immunol 3 2003 123-132
26. Chatenoud L. Baudrihaye M.F. Kreis H. Goldstein G. Schindler J. Bach J.F. Human in vivo antigenic modulation induced by the anti-T cell OKT3 monoclonal antibody Eur J Immunol 12 1982 979-982
27. Chatenoud L. Baudrihaye M.F. Chkoff N. Kreis H. Goldstein G. Bach J.F. Restriction of the human in vivo immune response against the mouse monoclonal antibody OKT3 J Immunol 137 1986 830-838
28. Wong J.T. Colvin R.B. Selective reduction and proliferation of the CD4+ and CD8+ T cell subsets with bispecific monoclonal antibodies: evidence for inter-T cell-mediated cytolysis Clin Immunol Immunopathol 58 1991 236-250
29. Wesselborg S. Janssen O. Kabelitz D. Induction of activation-driven death (apoptosis) in activated but not resting peripheral blood T cells J Immunol 150 1993 4338-4345
30. Chatenoud L. Bach J.F. Antigenic modulation: a major mechanism of antibody action Immunol Today 5 1984 20-25
31. Nicolls M.R. Aversa G.G. Pearce N.W. Spinelli A. Berger M.F. Gurley K.E. Hall B.M. Induction of long-term specific tolerance to allografts in rats by therapy with an anti-CD3-like monoclonal antibody Transplantation 55 1993 459-468
32. Plain K.M. Chen J. Merten S. He X.Y. Hall B.M. Induction of specific tolerance to allografts in rats by therapy with non-mitogenic, non-depleting anti-CD3 monoclonal antibody: association with TH2 cytokines not anergy Transplantation 67 1999 605-613
33. Belghith M. Bluestone J.A. Barriot S. Megret J. Bach J.F. Chatenoud L. TGF-beta-dependent mechanisms mediate restoration of self-tolerance induced by antibodies to CD3 in overt autoimmune diabetes Nat Med 9 2003 1202-1208
34. Chatenoud L. Salomon B. Bluestone J.A. Suppressor T cells-they're back and critical for regulation of autoimmunity! Immunol Rev 182 2001 149-163
35. Sakaguchi S. Regulatory T cells: key controllers of immunologic self-tolerance Cell 101 2000 455-458
36. Friend P.J. Hale G. Chatenoud L. Rebello P. Bradley J. Thiru S. Phillips J.M. Waldmann H. Phase I study of an engineered aglycosylated humanized CD3 antibody in renal transplant rejection Transplantation 68 1999 1632-1637
37. Woodle E.S. Xu D. Zivin R.A. Auger J. Charette J. O'laughlin R. Peace D. Jollife L.K. Haverty T. Bluestone J.A. et al. Phase I trial of a humanized, Fc receptor nonbinding OKT3 antibody, huOKT3gamma1(Ala-Ala) in the treatment of acute renal allograft rejection Transplantation 68 1999 608-616
38. Herold K.C. Hagopian W. Auger J.A. Poumian Ruiz E. Taylor L. Donaldson D. Gitelman S.E. Harlan D.M. Xu D. Zivin R.A. et al. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus N Engl J Med 346 2002 1692-1698
39. Utset T.O. Auger J.A. Peace D. Zivin R.A. Xu D. Jolliffe L. Alegre M.L. Bluestone J.A. Clark M.R. Modified anti-CD3 therapy in psoriatic arthritis: a phase I/II clinical trial J Rheumatol 29 2002 1907-1913
40. Hering B.J. Kandaswamy R. Harmon J.V. Ansite J.D. Clemmings S.M. Sakai T. Paraskevas S. Eckman P.M. Sageshima J. Nakano M. et al. Transplantation of cultured islets from two-layer preserved pancreases in type 1 diabetes with anti-CD3 antibody Am J Transplant 4 2004 390-401